Antifungal efficacy, safety, and single-dose pharmacokinetics of LY303366, a novel echinocandin B, in experimental pulmonary aspergillosis in persistently neutropenic rabbits.
about
In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungiEfficacy of FK463, a new lipopeptide antifungal agent, in mouse models of disseminated candidiasis and aspergillosisEfficacy of FK463, a new lipopeptide antifungal agent, in mouse models of pulmonary aspergillosisEfficacies of two new antifungal agents, the triazole ravuconazole and the echinocandin LY-303366, in an experimental model of invasive aspergillosisRapamycin and less immunosuppressive analogs are toxic to Candida albicans and Cryptococcus neoformans via FKBP12-dependent inhibition of TORPharmacokinetics of caspofungin acetate to guide optimal dosing in cats.Toxicity of LY303366, an echinocandin antifungal, in mice pretreated with glucocorticoidsDosage-dependent antifungal efficacy of V-echinocandin (LY303366) against experimental fluconazole-resistant oropharyngeal and esophageal candidiasis.Compartmental pharmacokinetics of the antifungal echinocandin caspofungin (MK-0991) in rabbits.Pharmacokinetic and pharmacodynamic modeling of anidulafungin (LY303366): reappraisal of its efficacy in neutropenic animal models of opportunistic mycoses using optimal plasma samplingQuantitative PCR assay to measure Aspergillus fumigatus burden in a murine model of disseminated aspergillosis: demonstration of efficacy of caspofungin acetate.Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections.Effect of amphotericin B and micafungin combination on survival, histopathology, and fungal burden in experimental aspergillosis in the p47phox-/- mouse model of chronic granulomatous disease.Antifungal pharmacokinetics and pharmacodynamicsIn vitro interaction of voriconazole and anidulafungin against triazole-resistant Aspergillus fumigatus.Pharmacokinetics and Concentration-Dependent Efficacy of Isavuconazole for Treatment of Experimental Invasive Pulmonary Aspergillosis.Efficacy of single-dose liposomal amphotericin B or micafungin prophylaxis in a neutropenic murine model of invasive pulmonary aspergillosis.Pediatric antifungal agents.In vitro activity of anidulafungin against selected clinically important mold isolatesEfficacy of the investigational echinocandin ASP9726 in a guinea pig model of invasive pulmonary aspergillosis.The antifungal echinocandin caspofungin acetate kills growing cells of Aspergillus fumigatus in vitro.Antifungal therapy of murine Aspergillus terreus infection.Fungal echinocandin resistance.In vitro activity and in vivo efficacy of anidulafungin in murine infections by Aspergillus flavus.Anidulafungin in combination with amphotericin B against Aspergillus fumigatus.In vitro synergy testing of anidulafungin with itraconazole, voriconazole, and amphotericin B against Aspergillus spp. and Fusarium spp.Caspofungin prolongs survival of transiently neutropenic rats with advanced-stage invasive pulmonary aspergillosis.
P2860
Q28343817-3BFD1DBB-8F35-4D11-AFC0-450A7856CE7EQ28343919-2C5E9639-502C-453B-B734-DF3C1D553849Q28343922-88798112-F7FB-4E4A-A408-DEFD34370882Q28344947-B3B2C1E1-8376-4BA2-BB3B-C48AE0322BF0Q28361576-FF6F1D76-DA87-496A-A933-FF426035A0D8Q33757912-E5B19132-E278-431F-B71F-18D881BCA49EQ33978727-64524F39-1A00-45B3-A81A-25934295DA0CQ33981387-B1AC13E3-1CF3-4A51-AE2E-246CD948287AQ33981480-3A25823E-CB36-497B-A2B8-48EB40A31E98Q33983159-1E050306-E68A-4FF9-B00D-768AC90BD76AQ33983618-12BED2B1-B120-4AF5-96D2-2A134FB42047Q34352100-E1B19B84-9FD3-4CE5-859A-3E66F26DE412Q34352222-D9A0E4EF-21EB-43CD-BA33-C3B0547C82BAQ35663841-DAED8E08-392A-444A-ABF6-B45E80AB28D7Q36558484-D565A103-93C3-45B9-A6BF-96824506D3ABQ36887855-8830F51A-AC33-427A-AFD2-DD913C91EBB8Q36949553-D954BECC-745D-482F-9043-0CA818BCE4DAQ37594515-F267C5A4-EC13-4B95-8D7E-2834ECC1B0D8Q37734590-188FC6B9-66DD-4B43-8B91-CE74B305D9B0Q39565084-698D022E-F1FF-40D9-9251-6984B168B0FCQ39652699-D1EBD816-D7D7-4234-A29C-A2A60969E8F2Q40164992-AC83D7A8-C1D3-4081-BE34-ED85D8B9AD1EQ41848811-8F8F0654-1BF4-4B74-B39D-0B3718F38518Q41857220-449D07A7-1D04-4B63-A2DF-3CE9BB83CFBDQ42545764-21363394-F351-4A0B-9E06-A6AC52C9D8A8Q42949201-CCD92874-45BC-42D2-B4D0-A893BBA992A2Q43111770-94993D61-B710-444B-9DF6-FA69D5E7282F
P2860
Antifungal efficacy, safety, and single-dose pharmacokinetics of LY303366, a novel echinocandin B, in experimental pulmonary aspergillosis in persistently neutropenic rabbits.
description
1998 nî lūn-bûn
@nan
1998 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
Antifungal efficacy, safety, a ...... rsistently neutropenic rabbits
@nl
Antifungal efficacy, safety, a ...... sistently neutropenic rabbits.
@ast
Antifungal efficacy, safety, a ...... sistently neutropenic rabbits.
@en
type
label
Antifungal efficacy, safety, a ...... rsistently neutropenic rabbits
@nl
Antifungal efficacy, safety, a ...... sistently neutropenic rabbits.
@ast
Antifungal efficacy, safety, a ...... sistently neutropenic rabbits.
@en
prefLabel
Antifungal efficacy, safety, a ...... rsistently neutropenic rabbits
@nl
Antifungal efficacy, safety, a ...... sistently neutropenic rabbits.
@ast
Antifungal efficacy, safety, a ...... sistently neutropenic rabbits.
@en
P2093
P2860
P1476
Antifungal efficacy, safety, a ...... sistently neutropenic rabbits.
@en
P2093
C L McMillian
D P Callender
R L Schaufele
R Petraitiene
V Petraitis
P2860
P304
P407
P577
1998-11-01T00:00:00Z